Precigen CEO Helen Sabzevari to Depart, Transition to Consulting Role
Ticker: PGEN · Form: 8-K · Filed: Feb 8, 2024 · CIK: 1356090
| Field | Detail |
|---|---|
| Company | Precigen, Inc. (PGEN) |
| Form Type | 8-K |
| Filed Date | Feb 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: executive-change, leadership, corporate-governance
TL;DR
**PGEN's CEO is out, moving to a consulting gig until August 31, 2024.**
AI Summary
Precigen, Inc. (PGEN) announced on February 2, 2024, that Helen Sabzevari, Ph.D., will step down as President and CEO and resign from the Board of Directors, effective February 29, 2024. She will transition to a consulting role until August 31, 2024, receiving her current base salary and benefits. This matters to investors because a change in top leadership can signal a shift in company strategy or performance, potentially impacting future stock value.
Why It Matters
A change in leadership at the CEO level can significantly influence a company's strategic direction and operational execution, directly affecting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — CEO departures introduce uncertainty regarding future company strategy and stability, which can lead to stock volatility.
Analyst Insight
A smart investor would monitor for news regarding Helen Sabzevari's replacement and any subsequent strategic shifts, as leadership changes can significantly impact future company direction and stock performance.
Key Players & Entities
- Helen Sabzevari (person) — President and CEO of Precigen, Inc., resigning and transitioning to a consulting role
- Precigen, Inc. (company) — the registrant in this 8-K filing
- February 2, 2024 (date) — date of earliest event reported
- February 29, 2024 (date) — effective date of Helen Sabzevari's resignation as CEO and from the Board
- August 31, 2024 (date) — end date of Helen Sabzevari's consulting agreement
Forward-Looking Statements
- Precigen's stock (PGEN) may experience short-term volatility due to leadership uncertainty. (PGEN) — medium confidence, target: 2024-03-31
- Precigen will announce a new CEO or interim CEO by the end of Q1 2024. (Precigen, Inc.) — medium confidence, target: 2024-03-31
FAQ
What is the primary event reported in this 8-K filing by Precigen, Inc.?
The primary event reported is the departure of Helen Sabzevari, Ph.D., from her roles as President and Chief Executive Officer and as a member of the Board of Directors of Precigen, Inc., effective February 29, 2024.
When is Helen Sabzevari's resignation from her executive and board positions effective?
Helen Sabzevari's resignation as President and CEO and from the Board of Directors is effective as of February 29, 2024, as stated in the filing with the earliest event reported on February 2, 2024.
What will be Helen Sabzevari's role with Precigen, Inc. after her resignation as CEO?
After her resignation, Helen Sabzevari will transition into a consulting role for Precigen, Inc., which is expected to continue until August 31, 2024.
What compensation will Helen Sabzevari receive during her consulting period?
During her consulting period, Helen Sabzevari will continue to receive her current base salary and benefits, as detailed in the filing.
What is Precigen, Inc.'s trading symbol and on which exchange is it registered?
Precigen, Inc.'s trading symbol is PGEN, and its Common Stock, No Par Value, is registered on the Nasdaq Global Select Market.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-02-08 16:25:09
Filing Documents
- dp206486_8k.htm (8-K) — 22KB
- 0000950103-24-001932.txt ( ) — 189KB
- pgen-20240202.xsd (EX-101.SCH) — 3KB
- pgen-20240202_lab.xml (EX-101.LAB) — 33KB
- pgen-20240202_pre.xml (EX-101.PRE) — 22KB
- dp206486_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Precigen, Inc. By: /s/ Donald P. Lehr Donald P. Lehr Chief Legal Officer Dated: February 8, 2024